Los Angeles, CA: Subjects who consume commercially available CBD products report improvements in their overall well-being as compared to those taking a placebo, according to data published in the journal Integrative Medicine Reports.
A team of investigators affiliated with the University of California, Los Angeles and with the Scripps Institute assessed the health and safety of 13 commercially available CBD products in a cohort of over 2,800 participants. Subjects were randomly assigned to consume either CBD or a placebo for a period of 4 weeks.
Researchers reported: “Well-being, anxiety, sleep disturbance, and pain significantly improved among those assigned to take a CBD product relative to waitlist controls. Among those assigned to a CBD product, the percentage of individuals with a given condition who experienced an improvement which could be considered clinically meaningful or important was 46.6 percent for anxiety; 47.9 percent for sleep disturbance, and 35.2 percent for pain. … [A]ll products in the study exhibited a favorable safety profile; no severe side effects were reported.”
They concluded: “Our results suggest that the commercially available CBD products included in this study are safe and may serve as potentially effective complementary therapies for management of anxiety, sleep disturbance, and pain. These effects appear independent of the prior CBD use and product spectrum.”
Prior analyses of commercially available CBD products have raised concerns about their purity and potency. Survey data compiled by the National Consumers League in 2020 determined that more than eight in ten US voters desire greater federal regulatory oversight over the labeling and marketing of commercially available CBD products.
Full text of the study, “The safety and effectiveness of commercially available cannabidiol products for health and well-being: A randomized, multi-arm, open-label waitlist-controlled trial,” appears in Integrative Medicine Reports.